Femoral placement of a totally implantable venous access port with spontaneous catheter fracture: case report.

Catheter fracture Femoral vein Late complication Totally implanted venous access port

Journal

CVIR endovascular
ISSN: 2520-8934
Titre abrégé: CVIR Endovasc
Pays: Switzerland
ID NLM: 101738484

Informations de publication

Date de publication:
06 Jan 2020
Historique:
received: 21 09 2019
accepted: 23 12 2019
entrez: 7 2 2020
pubmed: 7 2 2020
medline: 7 2 2020
Statut: epublish

Résumé

The incidence of catheter fracture after standard positioning of a totally implantable venous access port (TIVAP) is reported to be 1.1%-5.0%; however, the incidence of catheter fracture after TIVAP implantation at a femoral site remains unclear. In a 30-year-old man with angiosarcoma of the right atrium, tumor embolism was observed from the left brachiocephalic vein to the superior vena cava. A TIVAP was implanted in the right femur. A catheter fracture was spontaneously observed after 7 months. To the best of our knowledge, this is the first case of catheter fracture in a TIVAP implantation at a femoral site.

Sections du résumé

BACKGROUND BACKGROUND
The incidence of catheter fracture after standard positioning of a totally implantable venous access port (TIVAP) is reported to be 1.1%-5.0%; however, the incidence of catheter fracture after TIVAP implantation at a femoral site remains unclear.
CASE PRESENTATION METHODS
In a 30-year-old man with angiosarcoma of the right atrium, tumor embolism was observed from the left brachiocephalic vein to the superior vena cava. A TIVAP was implanted in the right femur. A catheter fracture was spontaneously observed after 7 months.
CONCLUSIONS CONCLUSIONS
To the best of our knowledge, this is the first case of catheter fracture in a TIVAP implantation at a femoral site.

Identifiants

pubmed: 32027011
doi: 10.1186/s42155-019-0094-9
pii: 10.1186/s42155-019-0094-9
pmc: PMC6966363
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2

Références

Geburtshilfe Frauenheilkd. 2016 Jan;76(1):53-58
pubmed: 26855441
Eur J Cancer. 2016 May;59:113-124
pubmed: 27023050
J Vasc Access. 2019 Sep;20(5):563-566
pubmed: 30854915
J Surg Oncol. 2008 Sep 1;98(3):197-9
pubmed: 18704915
J Vasc Access. 2014 Sep-Oct;15(5):391-5
pubmed: 25041921
Eur J Surg Oncol. 2004 Sep;30(7):771-5
pubmed: 15296992
Lancet Oncol. 2002 Nov;3(11):684-92
pubmed: 12424071
Support Care Cancer. 2014 Feb;22(2):383-7
pubmed: 24061782
J Surg Oncol. 2016 Dec;114(8):1024-1028
pubmed: 27658579
Eur J Surg Oncol. 1996 Apr;22(2):162-5
pubmed: 8608834

Auteurs

Tomohiro Kondo (T)

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.

Shigemi Matsumoto (S)

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. motocame@kuhp.kyoto-u.ac.jp.

Keitaro Doi (K)

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.

Motoo Nomura (M)

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.

Manabu Muto (M)

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.

Classifications MeSH